GSK's pre-filled shingles vaccine accepted for review by EMA

(Sharecast News) - GSK has announced that a pre-filled syringe version of its Shingrix shingles vaccine has been accepted for review by the European Medicines Agency. Shringrix, which has already been administered to over 25m people across the continent since 2018, currently comes as a separate powder and liquid adjuvant, which need to be reconstituted in separate vials prior to administration.

A pre-filled solution, if approved, would offer a more convenient option for physicians, pharmacists and other healthcare professionals, GSK said.

The pre-filled version, which was approved by the US Food and Drug Administration earlier this month, is also being targeted at other markets, GSK said.

It is estimated that one in three adult will develop shingles in their lifetime, and 30% can experience post-herpetic neuralgia or PHN, a long-lasting nerve pain that can last weeks, month or in some cases years.